22261520|t|Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging.
22261520|a|BACKGROUND: The noninvasive evaluation of nigrostriatal dopaminergic integrity by PET can provide useful information for the differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). OBJECTIVES: To evaluate the diagnostic potential of imaging striatal monoaminergic terminal integrity with the novel vesicular monoamine transporter type 2 (VMAT2) radioligand [(18)F]AV-133 and PET to distinguish DLB from AD. METHODS: Fifty participants [9 DLB, 11 AD, 20 Parkinson's disease (PD) and 10 healthy age-matched control subjects (HC)] underwent [(18)F]AV-133 PET studies. Additionally, 20 participants underwent amyloid imaging PET scans with either [(11)C]PiB or (18)F-florbetaben. VMAT2 density was calculated through normalized tissue uptake value ratios (R(T)) at 120-140 min after injection using the primary visual or the cerebellar cortex as reference region. Comparison of the R(T) for [(18)F]AV-133 was done between the different clinical diagnostic groups. RESULTS: Significantly lower striatal VMAT2 densities were observed in DLB and PD when compared to AD and HC, especially in the posterior putamen. In contrast to PD and DLB, no reductions were observed in AD patients when compared to HC. CONCLUSIONS: [(18)F]AV-133 allows assessment of nigrostriatal degeneration in Lewy body diseases. In contrast to amyloid imaging, VMAT2 imaging with [(18)F]AV-133 can robustly detect reductions of dopaminergic nigrostriatal afferents in DLB patients, assisting in the differential diagnosis from AD.
22261520	26	45	Alzheimer's disease	Disease	MESH:D000544
22261520	50	75	dementia with Lewy bodies	Disease	MESH:D020961
22261520	80	85	VMAT2	Gene	6571
22261520	90	97	amyloid	Disease	MESH:C000718787
22261520	263	288	dementia with Lewy bodies	Disease	MESH:D020961
22261520	290	293	DLB	Disease	MESH:D020961
22261520	299	318	Alzheimer's disease	Disease	MESH:D000544
22261520	320	322	AD	Disease	MESH:D000544
22261520	442	480	vesicular monoamine transporter type 2	Gene	6571
22261520	482	487	VMAT2	Gene	6571
22261520	503	514	18)F]AV-133	Chemical	MESH:C549477
22261520	538	541	DLB	Disease	MESH:D020961
22261520	547	549	AD	Disease	MESH:D000544
22261520	582	585	DLB	Disease	MESH:D020961
22261520	590	592	AD	Disease	MESH:D000544
22261520	597	616	Parkinson's disease	Disease	MESH:D010300
22261520	618	620	PD	Disease	MESH:D010300
22261520	684	695	18)F]AV-133	Chemical	MESH:C549477
22261520	749	756	amyloid	Disease	MESH:C000718787
22261520	787	797	[(11)C]PiB	Chemical	MESH:C475519
22261520	801	818	(18)F-florbetaben	Chemical	MESH:C527756
22261520	820	825	VMAT2	Gene	6571
22261520	1033	1044	18)F]AV-133	Chemical	MESH:C549477
22261520	1142	1147	VMAT2	Gene	6571
22261520	1175	1178	DLB	Disease	MESH:D020961
22261520	1183	1185	PD	Disease	MESH:D010300
22261520	1203	1205	AD	Disease	MESH:D000544
22261520	1266	1268	PD	Disease	MESH:D010300
22261520	1273	1276	DLB	Disease	MESH:D020961
22261520	1309	1311	AD	Disease	MESH:D000544
22261520	1312	1320	patients	Species	9606
22261520	1357	1368	18)F]AV-133	Chemical	MESH:C549477
22261520	1390	1416	nigrostriatal degeneration	Disease	MESH:D009410
22261520	1420	1438	Lewy body diseases	Disease	MESH:D020961
22261520	1472	1477	VMAT2	Gene	6571
22261520	1493	1504	18)F]AV-133	Chemical	MESH:C549477
22261520	1579	1582	DLB	Disease	MESH:D020961
22261520	1583	1591	patients	Species	9606
22261520	1638	1640	AD	Disease	MESH:D000544
22261520	Association	MESH:C527756	MESH:C000718787
22261520	Negative_Correlation	MESH:D020961	6571
22261520	Negative_Correlation	MESH:D010300	6571
22261520	Negative_Correlation	MESH:C475519	MESH:C000718787
22261520	Negative_Correlation	MESH:C549477	6571
22261520	Association	MESH:D000544	6571
22261520	Negative_Correlation	MESH:C549477	MESH:D009410
22261520	Negative_Correlation	MESH:C549477	MESH:D020961

